Influenza A vaccines - Takeda

Drug Profile

Influenza A vaccines - Takeda

Alternative Names: BLB-750; Cell cultured influenza vaccine H5N1 TAKEDA 1mL; Cell cultured influenza vaccine H5N1 TAKEDA 5ml; Cell cultured influenza vaccine prototype TAKEDA 1mL; Cell cultured influenza vaccine prototype TAKEDA 5ml; Pandemic influenza vaccines - Takeda/Ology Bioservices

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype; Influenza A virus infections

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 06 Jun 2017 No recent reports on development identified - Registered for Influenza-A virus H5N1 subtype infection, and other Influenza-A virus infections (Prevention) in Japan (Parenteral)
  • 25 Apr 2014 Takeda receives supplemental subsidy from the Japanese Government for cell culture-based pandemic vaccine development in Influenza A infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top